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Abstract
Glioblastomas (GBM) are highly radioresistant and lethal brain tumors. Ionizing radiation (IR)-
induced DNA double-strand breaks (DSBs) are a risk factor for the development of GBM. In this 
study, we systematically examined the contribution of IR-induced DSBs to GBM development 
using transgenic mouse models harboring brain-targeted deletions of key tumor suppressors 
frequently lost in GBM, namely Ink4a, Ink4b, Arf, and/or PTEN. Using low linear energy transfer 
(LET) X-rays to generate simple breaks or high LET Fe ions to generate complex breaks, we 
found that DSBs induce high-grade gliomas in these mice which, otherwise, do not develop 
gliomas spontaneously. Loss of Ink4a and Arf was sufficient to trigger IR-induced glioma 
development but additional loss of Ink4b significantly increased tumor incidence. We analyzed 
IR-induced tumors for copy number alterations (CNAs) to identify oncogenic changes that were 
generated and selected for as a consequence of stochastic DSB events. We found Met 
amplification to be the most significant oncogenic event in these radiation-induced gliomas. 
Importantly, Met activation resulted in expression of Sox2, a GBM cancer stem cell (CSC) 
marker, and was obligatory for tumor formation. In sum, these results indicate that radiation-
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induced DSBs cooperate with loss of Ink4 and Arf tumor suppressors to generate high-grade 
gliomas that are commonly driven by Met amplification and activation.
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Introduction
Glioblastoma (GBM) is the most common primary malignant brain tumor and is highly fatal 
despite aggressive treatment regimens that include surgical resection, radiotherapy, and 
chemotherapy (1-3). Following surgery, the residual tumor is commonly treated with 
cumulative radiation doses of 60 Gy or more. In spite of such aggressive treatment, tumor 
recurrence is quick and the relapsed tumor is highly therapy resistant. A clear understanding 
of factors contributing to glioblastoma development and recurrence is necessary for the 
formulation of effective therapeutic strategies. Exposure to ionizing radiation (IR) is the 
only known risk factor for developing these lethal brain tumors (4-9), and even low dose 
radiation exposure from CT scans has been reported to increase the risk of subsequent brain 
tumor development (10).
In order to directly examine the contribution of IR to GBM development, we intracranially 
irradiated a cohort of Nestin-Cre mice with brain-targeted deletions of Ink4a, Ink4b, Arf, 
and/or PTEN, tumor suppressor genes that are frequently lost in GBM (1-3). Two different 
types of IR, low linear energy transfer (LET) X-rays and high LET Fe ions, were used to 
induce simple and complex DNA double-strand breaks (DSBs), respectively (11-13). We 
found that exposure to IR precipitated the development of high-grade gliomas in these mice, 
with frequencies depending upon the combination of tumor suppressor gene deletion(s), as 
well as upon the radiation dose and quality. Strikingly, we found high levels of amplification 
of the Met receptor tyrosine kinase (RTK) to be the predominant genomic alteration in these 
IR-induced tumors. Interestingly, Met over-expression not only promoted tumorigenesis, but 
also conferred a stem cell phenotype via upregulation of Sox2 in these tumors.
Results and Discussion
Induction and repair of DNA double-strand breaks in the mouse brain
For this study, we used the following compound transgenic mouse lines in which GBM-
relevant tumor suppressor genes are conditionally deleted in the brain: 1) Nestin-
Cre;Ink4a/Arf+/+ (designated WT for wild type), 2) Nestin-Cre;Ink4a/Arff/f (designated 
Ink4a/Arf−/−), 3) Nestin-Cre;Ink4ab−/−;Arff/f (designated Ink4ab/Arf−/−), and 4) Nestin-
Cre;Ink4ab−/−;Arff/f;PTENf/+ (designated Ink4ab/Arf−/−;PTEN+/−) (Supplementary Table 1). 
We monitored the induction of DSBs, the most deleterious lesion inflicted by IR (14), in the 
brains of WT (Supplementary Figure S1a) and Ink4ab/Arf−/− (Figure 1a) mice that were 
intra-cranially irradiated with a single dose of 1 Gy Fe ions or 4 Gy X-rays (equitoxic doses 
based on the colony formation assay (15)). DSBs were quantified by counting γH2AX foci, 
a marker for DSBs, in brain sections at different times post-IR, as previously described (16). 
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DSBs were quantified in the two neurogenic niches, the subgranular zone (SGZ) and 
subventricular zone (SVZ) (17), as well as in the cortex and in astrocytes (GFAP-positive 
cells). At 1 hour post-IR, we observed the induction of DSBs in all regions of the WT and 
Ink4ab/Arf−/− mouse brains (Figure 1b and Supplementary Fig. 1b). By 12 hours post-IR, a 
high level of apoptosis (TUNEL positivity) was seen in the SVZ (Figure 1c and 
Supplementary Fig. 1c), along with a concomitant decrease in the number of proliferating 
(Ki67-positive) cells (Figure 1d and Supplementary Figure 1d), thus confirming the 
induction of DNA damage by both low and high LET IR. We found that DSBs induced by 
X-rays were rapidly repaired while those induced by Fe ions were persistent, as was evident 
from comparing residual breaks at 1 and 3 days post-IR (Figure 1b). Even at 1 month post-
IR, approximately 13% of Fe-irradiated cells harbored at least one γH2AX focus 
(Supplementary Fig. 1b). WT and Ink4ab/Arf−/− brains displayed similar DNA repair 
capabilities indicating that deletions of Ink4a, Ink4b, and Arf tumor suppressors did not 
affect the repair of IR-induced DSBs per se (Figure 1b).
Combined inactivation of Ink4a, Ink4b, and Arf cooperates with IR-induced DSBs to 
generate high-grade gliomas
WT, Ink4a/Arf−/−, Ink4ab/Arf−/−, and Ink4ab/Arf−/−;PTEN+/− mice, at 6-10 weeks of age, 
were irradiated intra-cranially with a single dose of 1 Gy Fe or with an equitoxic dose of 4 
Gy X-rays (Supplementary Table 1). Unlike typical mouse GBM models (1, 18), these mice 
lack a dominantly-acting oncogene and thus do not develop brain lesions spontaneously, 
except for a small percentage of Ink4ab/Arf−/−;PTEN+/− mice (Supplementary Table 1). 
Exposure to either X-rays or Fe ions resulted in brain tumors in mice with tumor suppressor 
gene deletions, but not in WT mice. Brain tumor incidence in Ink4ab/Arf−/− mice was higher 
than in Ink4a/Arf−/− mice (25% and 10%, respectively). Additional PTEN heterozygosity 
increased tumor incidence after Fe irradiation to 35% (Supplementary Table 1 and Figure 
2a). Four-fold lower doses of Fe ions compared to X-rays (1 Gy vs 4 Gy) were needed to 
achieve similar tumor frequencies. Thus, Fe ions appear to have an approximately 4-fold 
higher relative biological effectiveness (RBE) for transformation compared to X-rays, very 
similar to the RBE for cell killing in colony formation assays (15). Taken together, these 
results clearly indicate that DSBs, both simple and complex, can cooperate with deletions of 
the Ink4 and Arf genes to promote malignant transformation in the mouse brain.
All IR-induced tumors obtained were highly infiltrative, exhibiting markedly increased 
cellularity (Figure 2b), high mitotic activity, and pleomorphic nuclei, with areas of 
pseudopalisading necrosis (Figure 2c). These tumors were classified as high-grade glial 
tumors (Grade III or IV) after pathological examination, based on the World Health 
Organization classification system (1). Tumors from Ink4ab/Arf−/− mice (Figure 2d), as well 
as from other genotypes (Supplementary Figure 2), stained positive for Nestin, GFAP, NeuN 
and Olig2 to varying extents, all of which are classical human glioma markers (19). Tumors 
also showed elevated levels of phospho-Erk and phospho-Akt, indicating activation of Ras 
and Akt signaling pathways, respectively, and high numbers of Ki67-positive cells, 
indicating robust proliferation as seen in human GBM.
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IR-induced glioblastomas are characterized by a high frequency and amplitude of Met 
amplification
In order to identify genomic changes driving IR-induced gliomagenesis, we analyzed Fe-
induced tumors from Ink4ab/Arf−/− mice using array comparative genomic hybridization 
(aCGH) (Figure 3a). The data set was analyzed using the Genomic Identification of 
Significant Targets in Cancer (GISTIC) algorithm that identifies regions of copy number 
variation (CNV) that are more likely to drive cancer pathogenesis by emphasizing frequency 
of occurrence as well amplitude of the aberration (20). Upon analysis of 12 Ink4ab/Arf−/− 
tumors, we identified 76 genes with G scores >5 (Appendix). The most significant and 
frequent amplification (G score= 25.3), found present in ~42% (5/12) of tumors examined, 
localized to a small region on Chr6A2, where the RTK Met was the only gene spanned by 
the peak of the CNV (Figure 3a). The amplitude of Met amplification was high, with log2 
ratios typically above 3, implying more than 8 gene copies per cell (Figure 3b). Other RTKs 
implicated in glioma development, namely PDGFRβ and EGFR (1), were found to be 
amplified in 16.6% (2/12) and 8.3% (1/12) of tumors, respectively. Log2 ratios for these two 
genes were between 0.5 and 1, indicating low copy number amplification (Supplementary 
Figure 3a). Met amplification was largely confirmed by fluorescence in situ hybridization 
(FISH) analyses of 8 tumors that had been previously analyzed by aCGH (Supplementary 
Table 2). Amplification was predominantly in the form of extra-chromosomal double 
minutes (Figure 3c) similar to that reported for human GBM (21). In most tumors examined 
by FISH, Met amplification was uniform, with every tumor cell showing evidence of 
amplification, indicating that this was an early event in gliomagenesis in these models 
similar to that postulated for human GBM (22). A limited number of tumors derived from 
other genotypes and radiation types were also analyzed by aCGH and/or FISH and frequent 
Met amplification was observed in these IR-induced tumors (Supplementary Figure 3b and 
Supplementary Table 2). Finally, amplification correlated with robust Met expression and 
activation as confirmed by immunohistochemical staining of representative tumors with 
anti-Met and anti-phospho-Met antibodies, respectively (Figure 3d).
Met amplification in IR-induced tumors correlates with Sox2 expression and promotes 
tumorigenesis
We established ex vivo cultures from tumors obtained from X-ray or Feirradiated Ink4ab/
Arf−/− mice. However, even for tumors that were highly positive for Met, the derivative 
cultures showed barely detectable Met protein levels by Western blotting (Supplementary 
Figure 4a), indicating loss of Met double minutes due to absence of selection pressure under 
in vitro culture conditions. This phenomenon is similar to that reported for Met amplified in 
breast cancers (23), and is analogous to that seen with EGFR or EGFRvIII in human GBM 
cultures (24). We therefore re-expressed V5-tagged Met in a representative Fe-derived 
Ink4ab/Arf−/− tumor line (tumor ID#253). The Met re-expressing tumor line showed high 
levels of phosphorylated Met compared to control cells (parental tumor line expressing V5-
tagged β-Gal) (Figure 4a). A recent report highlighted a potential role for Met in maintaining 
a GBM CSC-like phenotype via up regulation of Sox2, a re-programming transcription 
factor involved in the maintenance of neural stem cells (NSC) (25). We, too, found that re-
expression of Met resulted in high levels of Sox2 expression (Figures 4a,b) and conferred an 
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ability to grow as neurospheres in serum-free NSC media (Figure 4c). Met expression also 
enhanced the ability of these cells to grow as colonies in soft agar indicating that these cells 
were highly transformed compared to the control cells (Figure 4d). Finally, to confirm the 
importance of Met in promoting tumorigenesis in our model system, we injected cells re-
expressing Met subcutaneously into nude mice. As few as 20,000 Met-expressing cells were 
sufficient to generate palpable tumors by 8 weeks indicating that these cells were highly 
tumorigenic (Figure 4e). By comparison, even 2.5 million control cells were unable to 
generate palpable tumors within this time frame. In a complementary set of experiments, we 
generated a tumor cell line with high levels of Met expression by passaging an ex vivo 
culture as an allograft (Supplementary Figure 4a). These cells showed significantly 
enhanced Sox2 expression (Supplementary Figure 4b,c) and stem cell and tumorigenic 
phenotypes (Supplementary Figure 4d,e) compared to the parental cultures (which had low 
levels of Met), and this was reversed by shRNA-mediated knockdown of Met. Importantly, 
higher levels of Sox2 expression were also seen in the radiation-induced gliomas with Met 
amplification compared to non-amplified tumors (Figure 3d).Taken together, these results 
indicate that Met amplification is important both for enhancing tumorigenicity as well as for 
promoting Sox2 expression and a CSC phenotype in the context of radiation-induced 
gliomas in these model systems.
In this study, we directly examined the role of IR-induced DSBs, in cooperation with 
existing tumor suppressor losses, in the development of high-grade gliomas using 
genetically accurate mouse GBM models. The greatest advantage of this approach is that, 
without forced expression of a dominant oncogene, it allows for the selection of genetic 
alterations arising from stochastic events that may play a crucial role in gliomagenesis. Our 
“sensitized” models, with targeted deletions of Ink4a, Ink4b, and Arf, are very appropriate 
for this study given that these loci are commonly deleted in about 50% of GBMs (26) and 
loss of these loci is suggested to be one of the earliest initiating events in gliomagenesis 
(27). Our results indicate that combined loss of these three tumor suppressors (Ink4a, Ink4b, 
and Arf), while insufficient for gliomagenesis per se, cooperate with IR-induced DSBs to 
efficiently induce high-grade gliomas. We find that the frequency of tumor formation 
depends both upon the tumor suppressor gene deletion(s) as well as upon the radiation dose 
and quality. We used two qualitatively different types of IR for this study, X- rays and Fe 
particles. While X-rays are commonly used for therapy, particle radiation is also being 
increasingly used in the clinic due to better dose distribution and higher RBE (11-13). In 
addition, heavier particles, such as Fe ions, are a common component of Galactic Cosmic 
Rays (GCR) and pose a clear cancer risk to astronauts, the magnitude of which remains to be 
quantified. We found that lower doses of Fe ions, compared to X-rays, are needed to 
generate tumors with the same frequency indicating that Fe ions have a higher transforming 
potential compared to X-rays. The higher transforming potential of Fe ions correlates with 
the slower repair of DSBs induced by these ions in vivo which is in accord with in vitro 
observations reported by us previously (15, 28). The slower repair observed with Fe ions is 
presumably due to the induction of clustered DNA damage that is inherently more difficult 
to repair (12, 13, 29) and also due to the propensity for such damage to undergo DNA end 
resection and be repaired by the slower process of homologous recombination (30-32). With 
both X-rays and Fe ions, we observed a significantly lower incidence of gliomas with loss of 
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Ink4a and Arf, compared to loss of Ink4a, Ink4b, and Arf, corroborating both our previous in 
vitro study showing that additional loss of Ink4b accompanies IR-induced transformation of 
Ink4a/Arf-null astrocytes (15) and an independent study demonstrating that Ink4b plays an 
important “backup” tumor suppressor role in the absence of Ink4a (33). Additional 
heterozygous loss of PTEN increases the frequency of brain tumors after Fe irradiation, in 
accord with the role of PTEN loss in promoting gliomagenesis in humans (1-3). Taken 
together, our results indicate that DSBs, whether simple or complex (i.e., resulting from X-
ray or Fe-irradiation), generate high-grade gliomas in these mouse models after exposure to 
an acute, clinically-relevant dose of IR, with Fe ions exhibiting at least a 4-fold higher 
transforming potential compared to X-rays.
Detailed analyses of the IR-induced tumors from Ink4ab/Arf−/− mice revealed that 
amplification of the RTK Met was strongly selected for during tumorigenesis and that Met 
expression conferred a high tumorigenic potential to the glioma cells. MET is frequently 
amplified or mutationally activated in many human cancers and triggers a diverse array of 
downstream signaling cascades that promote cell survival, growth, invasion, and metastasis 
of cancer cells (34, 35). Focal amplification of MET occurs in about 4% of human GBM 
(26). However, broad amplification of chromosome 7 (which harbors the MET gene) occurs 
in about 80% of primary GBM, and at least a third of chromosome 7 gain events are 
associated with overexpression of MET and/or its ligand HGF (20). A recent study mapping 
the evolution of glioblastomas in human patients identified MET amplification as an early 
event during gliomagenesis (22). Importantly, MET has recently been shown to be amplified 
and activated in GBM CSCs where it is involved in maintaining a stem cell-like phenotype 
by promoting the expression of re-programming transcription factors such as Nanog and 
Sox2 (25). A CSC-maintenance role for MET was bolstered by recent studies showing that 
MET amplification is a functional marker for GBM CSCs (36, 37). Our results, showing that 
Met promotes Sox2 expression and the ability of glioma cells to grow as neurospheres, 
support such a CSC-maintenance role for Met.
It has been reported that MET amplification in human tumors might be a consequence of 
DNA breakages occurring within chromosomal fragile sites (38); thus, it is conceivable that 
IR-induced DSBs might trigger MET amplification during radiotherapy of human GBM. 
Importantly, MET expression correlates with resistance to therapeutic agents (39-44) 
including IR (45). Thus, our results raise the possibility that recurrent tumors arising after 
radiotherapy might have a greater propensity for MET amplification, rendering them even 
more resistant to therapy compared to primary tumors. Indeed, in studies involving a limited 
number of matched pre- and post-irradiated (recurrent) tumor specimens, MET levels were 
found to be higher in recurrent tumors compared to the corresponding primary tumor; 
moreover, patients showing higher levels of MET induction after therapy had a significantly 
shorter median survival compared to patients with lower levels of MET induction (37, 46). 
A causal relationship between radiation and MET amplification may help explain why there 
is a lack of significant representation of GBMs showing concomitant over-expression of 
MET and Sox2 in the TCGA database where approximately 90% of the GBM specimens are 
primary tumors that did not receive radiotherapy (26). Our results, for the first time, 
demonstrate the process of radiation-induced gliomagenesis in genetically-defined mouse 
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GBM models and raise the possibility that Met amplification may drive glioblastoma 
development or recurrence upon exposure to IR. Taken together, these results have 
important implications not just for IR-induced gliomagenesis but also for the development 
of therapy-resistant recurrent tumors that arise after GBM radiotherapy.
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Figure 1. Induction and repair of DSBs in the mouse brain
(a) Ink4ab/Arf −/− mice were irradiated intra-cranially with 1 Gy of Fe ions or 4 Gy of X-
rays and DNA damage examined at the indicated time points. Fe ions with a kinetic energy 
of 600 MeV/nucleon were provided by the National Aeronautics and Space Administration 
(NASA) Space Radiation Laboratory at Brookhaven National Laboratory, as described 
previously (28). X-ray irradiations were carried out using an X-RAD 320 irradiator 
(Precision X-Ray). DNA damage was visualized by staining for γH2AX (red, Millipore, 
Billerica, MA); nuclei were stained with DAPI (blue). Immunofluorescence staining of 
tissue sections was performed as described previously (16). Representative pictures of the 
cortical region are shown. Mice were obtained from the Mouse Cancer Models Consortium 
and maintained in a FVB/NJ and C57BL6 mixed background. Nestin-Cre mice (47) were 
crossed with two previously described transgenic mouse lines, Ink4a/Arf f/f harboring floxed 
Ink4a and Arf genes (48) or Ink4ab−/−;Arf f/f, harboring germline inactivation of Ink4a and 
Ink4b, and a floxed Arf gene (33). Additional PTEN heterozygosity (PTENf/+) (49) was bred 
into the Ink4ab−/−;Arff/f background. All procedures for mouse experiments were performed 
under protocols approved by the Institutional Animal Care and Use Committees of the 
University of Texas Southwestern Medical Center and the Brookhaven National Laboratory. 
(b) DNA damage was quantified in the SGZ, SVZ, and cortex by calculating the percentage 
of nuclei with at least 1 γH2AX focus (y-axis) at the indicated times post-IR (x-axis). Initial 
damage was measured at 1 hour post-IR and mice were monitored up to 1 month post-IR. 
γH2AX data (1 to72 hours post-IR) for WT (Supplementary Figure S1a) and Ink4ab/Arf −/− 
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mice are plotted together to allow direct comparisons; data for the entire one-month time 
course are shown in Supplementary Figure S1b. Note higher percentage of cells with 
γH2AX foci in Fe-irradiated brains at 3 days post-IR and no major difference in repair 
capacity between WT and Ink4ab/Arf −/− mice. n = 3 mice per time point. Error bars, S.E.M. 
p-values for X-rays vs Fe ions are: **, p = 0.0072 (SGZ of WT mice); ***, p = 0.0003 (SGZ 
of Ink4ab/Arf−/− mice); **, p = 0.0085 (SVZ of WT mice); **, p = 0.0013 (SVZ of 
Ink4ab/Arf−/− mice); **, p = 0.0025 (cortex of WT mice); *, p = 0.0371 (cortex of 
Ink4ab/Arf−/− mice). Statistical significance was calculated by performing unpaired, two 
tailed t-tests using the Graphpad Prism software package. (c) Terminal deoxyribonucleotidyl 
transferase-mediated dUTP nick end labeling (TUNEL) staining was performed on brain 
sections of Ink4ab/Arf −/− and WT (Supplementary Figure S1c) mice at 12 and 24 hours 
post-IR. Note large numbers of apoptotic cells in the SVZ at 12 hours in response to both 
Fe- and X-ray irradiation. TUNEL assay was performed according to the manufacturer’s 
instructions using FragEL DNA Fragmentation Kit with colorimetric TdT-Enzyme 
(Calbiochem, Darmstadt, Germany) to detect fragmentation of DNA associated with 
apoptosis on formalin-fixed paraffin embedded tissue sections. (d) Proliferating cells in the 
SVZ of Ink4ab/Arf −/− and WT (Supplementary Figure S1d) mice were visualized by 
staining with anti-Ki67 antibody (green; Novocastra, Wetzlar, Germany). Note loss of Ki67-
positive cells after irradiation.
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Figure 2. DSBs cooperate with tumor suppressor gene loss to generate high-grade gliomas
(a) Kaplan-Meier curves showing percentages of Fe- or X-ray-irradiated mice surviving 
without intracranial lesions for the four different genetic backgrounds. n = 40 mice per 
group (numbers in parentheses indicate total number of glioblastomas observed in each 
cohort). Note higher incidence of tumor formation in Ink4ab/Arf−/− cohort compared to 
Ink4a/Arf−/− cohort. p = 0.0270 (Mock-IR vs X-rays or Fe for Ink4a/Arf−/− mice); p = 
0.0003 (Mock-IR vs X-rays or Fe for Ink4ab/Arf−/− mice); p = 0.0013 (Mock-IR vs X-rays 
for Ink4ab/Arf−/−;PTEN+/− mice); p < 0.0001 (Mock-IR vs Fe for Ink4ab/Arf−/−;PTEN+/− 
mice). Statistical significance was calculated by the logrank test using the Graphpad Prism 
software package. Mice were monitored for up to 9 months post-IR for onset of neurological 
symptoms (seizure, ataxia, lack of clasp reflex, or lack of balance) and for additional 
symptoms such as lethargy or weight loss. Mice exhibiting these symptoms or morbidity 
were sacrificed and examined for evidence of brain tumors by serial sectioning and 
Hematoxylin and Eosin (H&E) staining. Tumor classifications were assigned by a resident 
neuropathologist. To rule out occult lesions, all brains from asymptomatic mice were 
similarly screened at end of the experimental period. (b) Representative image of a tumor-
bearing Ink4ab/Arf−/− brain at 2 months post-IR compared to a normal mock-irradiated 
brain and Hematoxylin and Eosin (H&E)-stained section of a representative Ink4ab/Arf−/− 
brain harboring a glioma. Note infiltrative nature and hypercellularity of the lesion. (c) 
Tumors were classified as high-grade gliomas based on a range of histopathological features 
including – (i) high mitotic activity (inset shows magnified view of a mitotic nucleus), (ii) 
pleomorphic nuclei, and (iii) areas with pseudopalisading necrosis. (d) Immunofluorescence 
staining of Ink4ab/Arf−/− tumors for classical human glioma markers, Nestin (BD 
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Pharmingen, San Diego, CA), GFAP (Biocare Medical, Concord, CA), NeuN (Millipore, 
Billerica, MA), and Olig2 (Millipore, Billerica, MA) was carried out as described previously 
(16). Tumors were also stained for phospho-Erk1/Erk2 (Thr202/Tyr204) (Abcam, 
Cambridge, MA), phospho-Akt (Ser473) (Abcam, Cambridge, MA), and Ki67 (Novocastra, 
Wetzlar, Germany).
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Figure 3. High frequency and amplitude of Met amplification in radiation-induced gliomas
(a) aCGH schematic of Met locus showing region of amplification (blue lines) across 12 Fe-
derived tumor samples from Ink4ab/Arf−/− mice. Asterisks (*) indicate samples where 
region of amplification spanned the entire length of the Met locus. DNA was isolated from 
frozen tissues using the DNeasy Blood and Tissue Kit (Qiagen, Germantown, MD), 
following manufacturer’s protocol. aCGH was carried out as previously described (15) and 
data analyzed using Nexus Copy Number Analysis software (Biodiscovery, El Segundo, 
CA). To identify meaningful copy number variation (CNV) events, the Genomic 
Identification of Significant Targets in Cancer (GISTIC) algorithm was used (20). This 
method calculates a statistic (G score) that takes into account frequency of the occurrence as 
well as amplitude of the aberration, and also calculates statistical significance for each 
aberration. By this method, Met amplification (G score= 25.3) was identified to be the most 
significant genomic alteration in these tumors. n = 12. (b) Representative probe view of 
chromosomal region flanking the Met locus showing log2 ratios (y-axis) of individual 
probes along the chromosome (x-axis). (c) FISH analysis showing representative radiation-
induced tumors with normal, low, and high amplification levels of Met (red). A bacterial 
artificial chromosome (BAC) clone RP23-73G15 spanning the mouse Met gene was 
obtained from Invitrogen (Carlsbad, CA). DNA isolated from the BAC clone was labeled 
with Spectrum Orange dUTP by nick translation and used in FISH. FISH was performed on 
4 μm sections prepared from formalin-fixed paraffin-embedded tissues using standard 
hybridization methods (50). Hybridization signals were analyzed on DAPI counterstained 
slides using a Nikon Eclipse epi-fluorescence microscope equipped with Applied Imaging 
CytoVision software (San Jose, CA). FISH signal scoring on tissue sections was restricted to 
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tumor areas based on H&E sections. (d) Immunohistochemical staining of 4 representative 
Met amplified tumors compared to 2 non-amplified tumors from Fe-irradiated Ink4ab/Arf−/− 
mice. Amplification of Met correlates with higher Met expression, robust activation of Met 
(phospho-Met), and increased levels of Sox2 expression. IHC was carried out using 
ImmPRESS peroxidaseconjugated secondary antibodies and the ImmPACT DAB 
peroxidase substrate (Vector Laboratories, Burlingame, CA), as specified by manufacturer. 
Antibodies used for IHC were anti-phospho-Met (Tyr1234/1235), anti-Met (Cell Signaling, 
Danvers, MA), and anti-Sox2 (Abcam, Cambridge, MA).
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Figure 4. Met expression is associated with induction of Sox2 expression and high tumorigenic 
potential
(a) Western analysis of a representative Fe-derived tumor line (parental tumor ID#253), 
deficient in Ink4a, Ink4b, and Arf, and ectopically expressing V5-tagged Met or β-Gal as 
control. Primary astrocytes from WT and Ink4ab/Arf−/− mice serve as positive and negative 
Western blotting controls, respectively. Note that overexpression and activation of Met 
correlates with induction of high levels of Sox2. Ex vivo tumor cultures were all maintained 
in Dulbecco’s Modified Eagle Medium (DMEM) containing 10% of a fetal bovine/newborn 
calf serum mixture and penicillin/streptomycin (50 mg/ml). To generate Met-expressing 
tumor cells, Met was sequentially cloned into pLenti6.3/V5-DEST vector using the Gateway 
Cloning system (Invitrogen, Carlsbad, CA) with pBabe-puro c-Met-WT as the starting 
vector (gift from Joan Brugge; Addgene, Cambridge, MA; plasmid #17493). Virus 
production was carried out using ViraPower Lentiviral Packaging Mix (Invitrogen, 
Carlsbad, CA), as specified by manufacturer. Cells were infected with viral particles at a 
multiplicity of infection (MOI) of 2 with 4μg/ml polybrene. Cells were maintained under 
selection with 4μg/ml blasticidin. Western blotting of whole-cell extracts was performed as 
described before (16). Antibodies used were anti-actin (Sigma, St Louis, MO), anti-
phospho-Met (Tyr1234/1235), anti-Met, anti-Ink4b (Cell Signaling, Danvers, MA), anti-
Sox2 (Abcam, Cambridge, MA), anti-Ink4a, anti-Arf (Santa Cruz, Dallas, TX), and anti-V5 
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(Invitrogen, Carlsbad, CA). (b) Immunofluorescence staining of Met-expressing and control 
cells showing correlation of Met expression (red) with Sox2 (green) was carried out as 
described previously (16). Antibodies used were anti-Met (Cell Signaling, Danvers, MA) 
and anti-Sox2 (Abcam, Cambridge, MA). (c) Bright field images of cells expressing β-Gal 
or Met growing as adherent cells in full serum, or as spheres in NSC media. Cells were 
plated in NSC media at single cell dilutions in 96-well plates to assay for sphere-formation. 
The percentage of cells forming neurospheres is plotted. n = 2. Note that control cells 
(expressing β-Gal) show no growth in NSC medium. NSC medium consisted of DMEM/
Ham’s F12 50/50 mix with EGF (20ug/ml), bFGF (25ug/ml), progesterone (20ug/ml), B-27 
and insulin/transferrin-selenium supplements, doxycycline (2mg/ml), penicillin/
streptomycin (50 mg/ml) and Fungizone antimycotic. (d) Tumorigenic potential of cells was 
assessed by colony formation in soft-agar. 1×104 cells were plated in 0.6% Bacto-agar. The 
percentage of cells forming colonies is plotted.n = 2. Error bars, S.E.M. ***, p = 0.009. 
Statistical significance was calculated by performing unpaired, two tailed t-tests using the 
Graphpad Prism software package. (e) Representative image of tumor resulting from sub-
cutaneous injection of cells expressing Met at approximately 50 days post-injection. Note 
absence of tumor formation by control cells (expressing β-Gal). Cells (as indicated) were 
suspended in Hank’s Buffered Salt Solution and 2×104, 1×105, 5×105, or 2.5×106 cells were 
subcutaneously injected into the flanks of 6-week-old Nu/Nu nude mice (Charles River 
Laboratories International, Wilmington, MA). Mice were monitored daily to determine days 
to palpability. Tumor development after injection of increasing numbers of Met-expressing 
(triangles) or control cells (crosses) is plotted. Plot shows the number of cells injected (x-
axis) versus days until the resulting tumor became palpable (y-axis). Top section of plot 
shows injections that failed to form tumors up to 8 weeks. Note that 2×104 Met-expressing 
cells were sufficient to form tumors while even 2.5×106 control cells failed to form tumors 
within 8 weeks.
Camacho et al. Page 17
Oncogene. Author manuscript; available in PMC 2015 August 19.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
